Abstract
Summary
The global Enbrel (Etanercept) and Biosimilar market size is projected to grow from US$ 6211.9 million in 2022 to US$ 7862.4 million in 2029; it is expected to grow at a CAGR of 3.4% from 2023 to 2029.
United States market for Enbrel (Etanercept) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Enbrel (Etanercept) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Enbrel (Etanercept) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Enbrel (Etanercept) and Biosimilar players cover Pfizer, Amgen, Samsung Bioepis, Novartis, 3s Bio and Lupin, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Etanercept is a medication used to manage and treat autoimmune conditions such as plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis. It is a biologic fusion protein in the TNF blocker class of medications.
LPI (LP Information)' newest research report, the “Enbrel (Etanercept) and Biosimilar Industry Forecast” looks at past sales and reviews total world Enbrel (Etanercept) and Biosimilar sales in 2022, providing a comprehensive analysis by region and market sector of projected Enbrel (Etanercept) and Biosimilar sales for 2023 through 2029. With Enbrel (Etanercept) and Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Enbrel (Etanercept) and Biosimilar industry.
This Insight Report provides a comprehensive analysis of the global Enbrel (Etanercept) and Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Enbrel (Etanercept) and Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Enbrel (Etanercept) and Biosimilar market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Enbrel (Etanercept) and Biosimilar and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Enbrel (Etanercept) and Biosimilar.
This report presents a comprehensive overview, market shares, and growth opportunities of Enbrel (Etanercept) and Biosimilar market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Syringe
Pen
Segmentation by application
Hospital
Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Amgen
Samsung Bioepis
Novartis
3s Bio
Lupin
Key Questions Addressed in this Report
What is the 10-year outlook for the global Enbrel (Etanercept) and Biosimilar market?
What factors are driving Enbrel (Etanercept) and Biosimilar market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Enbrel (Etanercept) and Biosimilar market opportunities vary by end market size?
How does Enbrel (Etanercept) and Biosimilar break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
United States market for Enbrel (Etanercept) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Enbrel (Etanercept) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Enbrel (Etanercept) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Enbrel (Etanercept) and Biosimilar players cover Pfizer, Amgen, Samsung Bioepis, Novartis, 3s Bio and Lupin, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Etanercept is a medication used to manage and treat autoimmune conditions such as plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis. It is a biologic fusion protein in the TNF blocker class of medications.
LPI (LP Information)' newest research report, the “Enbrel (Etanercept) and Biosimilar Industry Forecast” looks at past sales and reviews total world Enbrel (Etanercept) and Biosimilar sales in 2022, providing a comprehensive analysis by region and market sector of projected Enbrel (Etanercept) and Biosimilar sales for 2023 through 2029. With Enbrel (Etanercept) and Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Enbrel (Etanercept) and Biosimilar industry.
This Insight Report provides a comprehensive analysis of the global Enbrel (Etanercept) and Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Enbrel (Etanercept) and Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Enbrel (Etanercept) and Biosimilar market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Enbrel (Etanercept) and Biosimilar and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Enbrel (Etanercept) and Biosimilar.
This report presents a comprehensive overview, market shares, and growth opportunities of Enbrel (Etanercept) and Biosimilar market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Syringe
Pen
Segmentation by application
Hospital
Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Amgen
Samsung Bioepis
Novartis
3s Bio
Lupin
Key Questions Addressed in this Report
What is the 10-year outlook for the global Enbrel (Etanercept) and Biosimilar market?
What factors are driving Enbrel (Etanercept) and Biosimilar market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Enbrel (Etanercept) and Biosimilar market opportunities vary by end market size?
How does Enbrel (Etanercept) and Biosimilar break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Enbrel (Etanercept) and Biosimilar Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Enbrel (Etanercept) and Biosimilar by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Enbrel (Etanercept) and Biosimilar by Country/Region, 2018, 2022 & 2029
2.2 Enbrel (Etanercept) and Biosimilar Segment by Type
2.2.1 Syringe
2.2.2 Pen
2.3 Enbrel (Etanercept) and Biosimilar Sales by Type
2.3.1 Global Enbrel (Etanercept) and Biosimilar Sales Market Share by Type (2018-2023)
2.3.2 Global Enbrel (Etanercept) and Biosimilar Revenue and Market Share by Type (2018-2023)
2.3.3 Global Enbrel (Etanercept) and Biosimilar Sale Price by Type (2018-2023)
2.4 Enbrel (Etanercept) and Biosimilar Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.4.3 Other
2.5 Enbrel (Etanercept) and Biosimilar Sales by Application
2.5.1 Global Enbrel (Etanercept) and Biosimilar Sale Market Share by Application (2018-2023)
2.5.2 Global Enbrel (Etanercept) and Biosimilar Revenue and Market Share by Application (2018-2023)
2.5.3 Global Enbrel (Etanercept) and Biosimilar Sale Price by Application (2018-2023)
3 Global Enbrel (Etanercept) and Biosimilar by Company
3.1 Global Enbrel (Etanercept) and Biosimilar Breakdown Data by Company
3.1.1 Global Enbrel (Etanercept) and Biosimilar Annual Sales by Company (2018-2023)
3.1.2 Global Enbrel (Etanercept) and Biosimilar Sales Market Share by Company (2018-2023)
3.2 Global Enbrel (Etanercept) and Biosimilar Annual Revenue by Company (2018-2023)
3.2.1 Global Enbrel (Etanercept) and Biosimilar Revenue by Company (2018-2023)
3.2.2 Global Enbrel (Etanercept) and Biosimilar Revenue Market Share by Company (2018-2023)
3.3 Global Enbrel (Etanercept) and Biosimilar Sale Price by Company
3.4 Key Manufacturers Enbrel (Etanercept) and Biosimilar Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Enbrel (Etanercept) and Biosimilar Product Location Distribution
3.4.2 Players Enbrel (Etanercept) and Biosimilar Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Enbrel (Etanercept) and Biosimilar by Geographic Region
4.1 World Historic Enbrel (Etanercept) and Biosimilar Market Size by Geographic Region (2018-2023)
4.1.1 Global Enbrel (Etanercept) and Biosimilar Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Enbrel (Etanercept) and Biosimilar Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Enbrel (Etanercept) and Biosimilar Market Size by Country/Region (2018-2023)
4.2.1 Global Enbrel (Etanercept) and Biosimilar Annual Sales by Country/Region (2018-2023)
4.2.2 Global Enbrel (Etanercept) and Biosimilar Annual Revenue by Country/Region (2018-2023)
4.3 Americas Enbrel (Etanercept) and Biosimilar Sales Growth
4.4 APAC Enbrel (Etanercept) and Biosimilar Sales Growth
4.5 Europe Enbrel (Etanercept) and Biosimilar Sales Growth
4.6 Middle East & Africa Enbrel (Etanercept) and Biosimilar Sales Growth
5 Americas
5.1 Americas Enbrel (Etanercept) and Biosimilar Sales by Country
5.1.1 Americas Enbrel (Etanercept) and Biosimilar Sales by Country (2018-2023)
5.1.2 Americas Enbrel (Etanercept) and Biosimilar Revenue by Country (2018-2023)
5.2 Americas Enbrel (Etanercept) and Biosimilar Sales by Type
5.3 Americas Enbrel (Etanercept) and Biosimilar Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Enbrel (Etanercept) and Biosimilar Sales by Region
6.1.1 APAC Enbrel (Etanercept) and Biosimilar Sales by Region (2018-2023)
6.1.2 APAC Enbrel (Etanercept) and Biosimilar Revenue by Region (2018-2023)
6.2 APAC Enbrel (Etanercept) and Biosimilar Sales by Type
6.3 APAC Enbrel (Etanercept) and Biosimilar Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Enbrel (Etanercept) and Biosimilar by Country
7.1.1 Europe Enbrel (Etanercept) and Biosimilar Sales by Country (2018-2023)
7.1.2 Europe Enbrel (Etanercept) and Biosimilar Revenue by Country (2018-2023)
7.2 Europe Enbrel (Etanercept) and Biosimilar Sales by Type
7.3 Europe Enbrel (Etanercept) and Biosimilar Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Enbrel (Etanercept) and Biosimilar by Country
8.1.1 Middle East & Africa Enbrel (Etanercept) and Biosimilar Sales by Country (2018-2023)
8.1.2 Middle East & Africa Enbrel (Etanercept) and Biosimilar Revenue by Country (2018-2023)
8.2 Middle East & Africa Enbrel (Etanercept) and Biosimilar Sales by Type
8.3 Middle East & Africa Enbrel (Etanercept) and Biosimilar Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Enbrel (Etanercept) and Biosimilar
10.3 Manufacturing Process Analysis of Enbrel (Etanercept) and Biosimilar
10.4 Industry Chain Structure of Enbrel (Etanercept) and Biosimilar
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Enbrel (Etanercept) and Biosimilar Distributors
11.3 Enbrel (Etanercept) and Biosimilar Customer
12 World Forecast Review for Enbrel (Etanercept) and Biosimilar by Geographic Region
12.1 Global Enbrel (Etanercept) and Biosimilar Market Size Forecast by Region
12.1.1 Global Enbrel (Etanercept) and Biosimilar Forecast by Region (2024-2029)
12.1.2 Global Enbrel (Etanercept) and Biosimilar Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Enbrel (Etanercept) and Biosimilar Forecast by Type
12.7 Global Enbrel (Etanercept) and Biosimilar Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Enbrel (Etanercept) and Biosimilar Product Portfolios and Specifications
13.1.3 Pfizer Enbrel (Etanercept) and Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Amgen
13.2.1 Amgen Company Information
13.2.2 Amgen Enbrel (Etanercept) and Biosimilar Product Portfolios and Specifications
13.2.3 Amgen Enbrel (Etanercept) and Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Amgen Main Business Overview
13.2.5 Amgen Latest Developments
13.3 Samsung Bioepis
13.3.1 Samsung Bioepis Company Information
13.3.2 Samsung Bioepis Enbrel (Etanercept) and Biosimilar Product Portfolios and Specifications
13.3.3 Samsung Bioepis Enbrel (Etanercept) and Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Samsung Bioepis Main Business Overview
13.3.5 Samsung Bioepis Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Enbrel (Etanercept) and Biosimilar Product Portfolios and Specifications
13.4.3 Novartis Enbrel (Etanercept) and Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 3s Bio
13.5.1 3s Bio Company Information
13.5.2 3s Bio Enbrel (Etanercept) and Biosimilar Product Portfolios and Specifications
13.5.3 3s Bio Enbrel (Etanercept) and Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 3s Bio Main Business Overview
13.5.5 3s Bio Latest Developments
13.6 Lupin
13.6.1 Lupin Company Information
13.6.2 Lupin Enbrel (Etanercept) and Biosimilar Product Portfolios and Specifications
13.6.3 Lupin Enbrel (Etanercept) and Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Lupin Main Business Overview
13.6.5 Lupin Latest Developments
14 Research Findings and Conclusion